WO2008106659A3 - Methods of treating bipolar disorder and memory and/or cognitive impairment associated therewith - Google Patents

Methods of treating bipolar disorder and memory and/or cognitive impairment associated therewith Download PDF

Info

Publication number
WO2008106659A3
WO2008106659A3 PCT/US2008/055562 US2008055562W WO2008106659A3 WO 2008106659 A3 WO2008106659 A3 WO 2008106659A3 US 2008055562 W US2008055562 W US 2008055562W WO 2008106659 A3 WO2008106659 A3 WO 2008106659A3
Authority
WO
WIPO (PCT)
Prior art keywords
memory
cognitive impairment
associated therewith
impairment associated
methods
Prior art date
Application number
PCT/US2008/055562
Other languages
French (fr)
Other versions
WO2008106659A2 (en
Inventor
David Lowe
Christopher J Leonard
Vivo Michael De
Geoffrey Tombaugh
Original Assignee
Memory Pharm Corp
David Lowe
Christopher J Leonard
Vivo Michael De
Geoffrey Tombaugh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memory Pharm Corp, David Lowe, Christopher J Leonard, Vivo Michael De, Geoffrey Tombaugh filed Critical Memory Pharm Corp
Publication of WO2008106659A2 publication Critical patent/WO2008106659A2/en
Publication of WO2008106659A3 publication Critical patent/WO2008106659A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention is a method of treating or preventing mixed and/or manic episodes associated with bipolar I disorder or memory and/or cognitive impairment associated therewith in a patient in need thereof by administering an effective amount of at least one calcium channel modulator selected from (1 ) amlodipine, bepridil, clevidipine, felodipine, isradipine, lacidipine, lercanidipine, manidipine, niguldipine, nilvadipine, nisoldipine, or nitrendipine, or (2) the R-enantiomer of a 1,4-dihydropyridine compound, other than (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)- l,4- dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate.
PCT/US2008/055562 2007-03-01 2008-02-29 Methods of treating bipolar disorder and memory and/or cognitive impairment associated therewith WO2008106659A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89245507P 2007-03-01 2007-03-01
US60/892,455 2007-03-01

Publications (2)

Publication Number Publication Date
WO2008106659A2 WO2008106659A2 (en) 2008-09-04
WO2008106659A3 true WO2008106659A3 (en) 2008-10-16

Family

ID=39721861

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/055562 WO2008106659A2 (en) 2007-03-01 2008-02-29 Methods of treating bipolar disorder and memory and/or cognitive impairment associated therewith

Country Status (1)

Country Link
WO (1) WO2008106659A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820691B2 (en) 2006-08-28 2010-10-26 Medipropharma, Inc. Indoloquinoline compounds as calcium channel blockers
WO2014052849A1 (en) * 2012-09-28 2014-04-03 Elan Pharmaceuticals, Inc. Combination treatments for bipolar disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567271A (en) * 1977-06-20 1986-01-28 Sandoz Ltd. Benzoxadiazoles and benzothiadiazoles
US6458808B1 (en) * 2000-12-20 2002-10-01 Osmotica Corp. Pharmaceutical composition for the treatment of cognitive cerebrovascular disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567271A (en) * 1977-06-20 1986-01-28 Sandoz Ltd. Benzoxadiazoles and benzothiadiazoles
US6458808B1 (en) * 2000-12-20 2002-10-01 Osmotica Corp. Pharmaceutical composition for the treatment of cognitive cerebrovascular disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SINGH ET AL.: "Renewed Interest in Calcium Channel as Antimania Agents in the Third Millenium", HONG KONG JOURNAL OF PSYCHIATRY, vol. 14, no. 2, 2004, pages 12 - 15 *
SKOLNICK: "New Pharmacological Strategies", 1997, HUMANA PRESS, TOTOWA, NEW JERSEY, ISBN: 0806034690, article PUCILOWSKI ET AL.: "Calcium Channel Antagonists in Mood Disorders, in Antidepressants", pages: 81 - 102 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US8889190B2 (en) 2013-03-13 2014-11-18 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9555005B2 (en) 2013-03-15 2017-01-31 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules

Also Published As

Publication number Publication date
WO2008106659A2 (en) 2008-09-04

Similar Documents

Publication Publication Date Title
ATE399026T1 (en) COMPOSITIONS CONTAINING L-TYPE CALCIUM CANAL BLOCKERS AND CHOLINESTERASE INHIBITORS
WO2008106659A3 (en) Methods of treating bipolar disorder and memory and/or cognitive impairment associated therewith
WO2007022924A3 (en) Pharmaceutical compositions with melting point depressant agents and method of making same
WO2003099346A3 (en) Compositions and methods for coating medical implants
WO2005011582A3 (en) Compositions, methods, devices, and kits for maintaining or enhancing tooth whitening
WO2008005427A3 (en) Pdgf-biomatrix compositions and methods for treating rotator cuff injuries
WO2007092755A3 (en) Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
WO2007150075A3 (en) Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
EP1974722A3 (en) Modified dosage forms of tacrolimus
DE60143197D1 (en) CRYSTALLINE FORM OF 5-CHLORO-3- (4-METHANESULFONYLPHENYL) -6'-METHYL-Ä2,3'Ü BIPYRIDINYL AND METHOD OF MANUFACTURING THEREOF
IL166795A (en) N - aryl piperidine substituted biphenylcarboxamides, pharmaceutical composiitons comprising them and method for their preparation
SG113556A1 (en) Graft copolymers, method of making and compositions containing the same
WO2000004862A3 (en) Bioenhanced formulations comprising eprosartan in oral solid dosage form
WO2004069215A3 (en) Dental whitening compositions and methods
WO2005000194A3 (en) Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
ATE521611T1 (en) 1,4-DIHYDROPYRIDINE CONDENSED HETEROCYCLES, PRODUCTION METHOD, USE AND COMPOSITIONS THEREOF
WO2006085208A3 (en) Stable solid dosage forms of amlodipine and benazepril
WO2008123582A1 (en) Tetrahydroisoquinoline compound
WO2019008516A3 (en) Treatment of cancer with dihydropyridines
HUP0100844A2 (en) Method of increasing the biovaliability and tissue penetration of azithromycin
AU2003229835A1 (en) Compounds, compositions and method for transporting cyclosporin molecules through the blood brain barrier
WO2006015970A3 (en) Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic
PE20060946A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING LERCANIDIPINE
PE20011163A1 (en) TREATMENT OF KIDNEY DISORDERS
DE60210893D1 (en) Bolt, thread rolling jaw and method of manufacture of the bolt

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08731173

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08731173

Country of ref document: EP

Kind code of ref document: A2